Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Molecular and Cellular Biology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
TRANSCRIPTIONAL REGULATION

Interleukin-6-Specific Activation of the C/EBPδ Gene in Hepatocytes Is Mediated by Stat3 and Sp1

Carrie A. Cantwell, Esta Sterneck, Peter F. Johnson
Carrie A. Cantwell
Eukaryotic Transcriptional Regulation Group, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esta Sterneck
Eukaryotic Transcriptional Regulation Group, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter F. Johnson
Eukaryotic Transcriptional Regulation Group, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/MCB.18.4.2108
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Induction of C/EBPδ and C/EBPβ mRNAs by IL-6 or IFN-γ in hepatoma cell lines. (A) Northern blot analysis of 20 μg of total RNA from Hep3B or HepG2 cells cells treated with IL-6 or IFN-γ for the indicated times. Duplicate blots were hybridized with C/EBPδ or C/EBPβ probes and then with cyclophilin. (B) Northern blotting analysis of 20 μg of total RNAs from control Hep3B cells (lane 1), cells treated with cycloheximide (CHX) for 30, 60, and 120 min (lanes 2 to 4), and cells pretreated with cycloheximide for 30, 60, and 120 min followed by the addition of IL-6 for 2 h (lanes 5 to 7), IL-6 alone for 2 h (lane 8), or cycloheximide and IL-6 concurrently for 2 h (lane 9). The blots were hybridized sequentially with the indicated probes.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    DNA sequence of the murine C/EBPδ promoter and identification of several putative regulatory elements. The sequence extends from a ScaI site at −729 to position +12 relative to the transcription startsite. Endpoints of 5′ deletion mutants are indicated by brackets at −729, −322, −127, −81, and −36. Sequences corresponding to potential regulatory sites are boxed. The arrow denotes the transcription startsite (25).

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Identification of an IL-6-responsive region within the C/EBPδ promoter. Luciferase reporter constructs containing the indicated 5′ promoter deletions were cotransfected with pRSV β-gal into Hep3B cells. The luciferase data were normalized to β-galactosidase values to control for differences in transfection efficiencies. The values represent averages ± standard deviations of three independent experiments. Basal luciferase expression levels from each construct are shown relative to the value for (−127)-Luc. Basal expression from (−36)-Luc was detectable but was rounded to 0.0. Fold induction represents luciferase activity after IL-6 treatment relative to the basal level.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Analysis of APRE and Sp1 sites. (A) Diagram of mutations. The mutations were introduced into the APRE at −106 bp and the Sp1 sites at −117 and −53 bp. The wild-type sequences are indicated at the top, and the mutated sequences are shown below. The mutations were incorporated into the (−127)-Luc deletion construct. (B) Transient transfection assays of promoter mutants. The indicated promoter-reporter constructs were cotransfected with pRSV β-gal into Hep3B cells. The luciferase data were normalized to β-galactosidase activity. The values represent the averages of three to six independent experiments. The relative basal expression and fold induction values were determined as described in the legend to Fig. 3.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    The C/EBPδ APRE competes for binding of Stat3 to the α2-m APRE. (A) EMSA using the rat α2-m APRE, nuclear extracts (6.5 μg) from HepG2 cells, and NRS or Stat3-specific antibody (Ab) as indicated. The HepG2 cells were treated with IL-6 for 15 min. An upper complex (u) and a lower complex (l) appear in the IL-6-treated extracts (lane 3). The Stat3 antibody supershift complex (lane 4) is indicated. (B) Competition for Stat3 binding by the C/EBPδ APRE. Nuclear extracts (10 μg) from IL-6 treated HepG2 cells were incubated with Stat3-specific antibody and 10× (lanes 3 and 6), 30× (lanes 4 and 7), or 100× (lanes 5 and 8) molar excess of unlabeled wild-type (δAPRE) or mutant (δAPREm) binding site, as indicated. The rat α2-m APRE was used as a probe. The film was overexposed to emphasize the supershifted complex.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Selective binding of Stat3 to the C/EBPδ APRE. Nuclear extracts from control or IL-6-treated HepG2 cells were analyzed by EMSA using the wild-type or mutant C/EBPδ APRE probes and control antiserum or Stat1- or Stat3-specific antibody (Ab), as indicated. The film was overexposed to emphasize the supershift signal.

  • Fig. 7.
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Binding of nuclear proteins to the Sp1(−117) site. (A) Supershift analysis using an antibody (Ab) against Sp1. Nuclear extracts were prepared from control or IL-6-treated HepG2 cells by a method that maximizes the extraction of Sp1 (see Materials and Methods). The extracts were incubated with either NRS or an Sp1-specific antibody and the δAPRE/Sp1 or δAPRE probe. The supershift generated by the Sp1 antibody in lanes 2 and 4 is indicated. (B and C) Binding of recombinant Sp1 to the δAPRE/Sp1 (B) and δAPRE (C) probes. Recombinant human Sp1 (50 ng) was used alone (lanes 5 and 10) or mixed with 8 μg of HepG2 nuclear extract (optimized for Stat protein extraction) from control or IL-6-treated cells. Stat3 antibody was added to the indicated reactions. The lower panel is a longer exposure of the top portion of the gel to emphasize the Stat3 antibody supershift complex.

  • Fig. 8.
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    The C/EBPδ APRE confers IL-6 responsiveness to a heterologous promoter. One or four copies of the C/EBPδ APRE or six copies of the α2-m APRE were inserted upstream of the TK promoter. The constructs were tested for induction by IL-6 after transfection into Hep3B cells as described in the legend to Fig. 3.

  • Fig. 9.
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    Stat3 mediates IL-6-induced expression from the C/EBPδ promoter. (A) Stat3 but not Stat1 transactivates the C/EBPδ promoter. The (−127)-Luc construct was cotransfected into Hep3B cells with expression vectors for Stat1 or Stat3 or the parental pCDNA1 vector, together with pRSV β-gal as an internal standard, and tested for basal and IL-6-induced luciferase expression. (B) Stat3 transactivation of C/EBPδ promoter mutants. The indicated deletion and point mutants (Fig. 3 and 4) were cotransfected with the Stat3 expression vector into Hep3B cells and tested for basal and IL-6-inducible luciferase expression. (C) Stat3 transactivates a heterologous promoter containing the C/EBPδ APRE. The indicated TK promoter-luciferase reporter constructs (Fig. 8) were cotransfected with the Stat3 expression plasmid into Hep3B cells and tested for basal and IL-6-inducible expression. The cell extracts were assayed for luciferase and β-galactosidase activities as described in Fig. 3. The values represent the averages of three to six independent experiments.

    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 10.

    Replacement of the C/EBPδ APRE with SBEs from ICAM-1 or C/EBPβ renders the promoter responsive to IFN-γ. (A) The C/EBPβ promoter contains an SBE that binds Stat1 and Stat3. A probe containing the putative SBE from the C/EBPβ promoter and Stat1- or α-Stat3-specific antibody (Ab) (lanes 3 and 4, respectively) were added to nuclear extracts from control (lane 1) or IL-6 treated (lanes 2 to 4) HepG2 cells and the reactions analyzed by EMSA. Antibody supershift species are indicated. (B) Comparison of SBE sequences from the C/EBPδ, C/EBPβ, and ICAM-1 promoters. Bases that differ from the C/EBPδ APRE sequence are underlined. (C) IL-6 and IFN-γ responsiveness of SBE swap mutants. Constructs in which the C/EBPδ APRE was exchanged with SBEs from the C/EBPβ or ICAM-1 genes were generated. These constructs and (−127)-Luc were cotransfected with pRSV β-gal into Hep3B cells and assayed for basal expression and IL-6 or IFN-γ inducibility. The values represent the average of three independent experiments. Relative basal expression was normalized to the (−127)-Luc level.

Tables

  • Figures
  • Table 1.

    Sequences and Stat binding properties of the C/EBPδ APRE and several known SBEs

    GeneSBEaBinding to:Reference(s)
    Stat1Stat3
    Murine C/EBPδ TCG TT CCC AGCAGCA −+This study
    Rat C/EBPβ TGT TT CCC AGAAGTT ++This study
    Rat α2-m GAATT CCC AGAA GGA ++ 17, 27  
    Human hemopexin TTT TT CCC GGCA GGA NDND 22
    Rat α1-acid glycoprotein TTT TT CCC AGAA GCC NDND 49
    Human haptoglobin CTT TT CCA GTAACAA NDND 32
    Human γ-fibrinogen TTC TT CCA GTAC ATG ND+ 51
    Human α1-antichymotrypsin CTA TT ACA G A AAA TT NDND 4
    Human C-reactive protein CTC TT CCC G A AGCTC ND+ 50
    Human LBP AGATT CCC AGTGCAG ND+ 41
    Murine junB CGCTT CCT G A CAGTG −+ 12
    Human c-fos CAGTT CCC GTCAA TC ++ 8
    Human ICAM-1 GCT TT CCC GGAAA CC ++ 7, 28
    • ↵a SBEs from a number of cytokine-inducible genes are shown in alignment with the C/EBPδ APRE. The sequences were aligned through the core palindromic TT-AA motif (boldface). In cases where there is more than one possibility for the -AA motif, the alternative bases are boldface and underlined.

    • b Binding (+) or lack of binding (−) of each SBE to Stat1 and Stat3, as determined by use of specific antibodies in supershift assays. ND, not determined.

PreviousNext
Back to top
Download PDF
Citation Tools
Interleukin-6-Specific Activation of the C/EBPδ Gene in Hepatocytes Is Mediated by Stat3 and Sp1
Carrie A. Cantwell, Esta Sterneck, Peter F. Johnson
Molecular and Cellular Biology Apr 1998, 18 (4) 2108-2117; DOI: 10.1128/MCB.18.4.2108

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Molecular and Cellular Biology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interleukin-6-Specific Activation of the C/EBPδ Gene in Hepatocytes Is Mediated by Stat3 and Sp1
(Your Name) has forwarded a page to you from Molecular and Cellular Biology
(Your Name) thought you would be interested in this article in Molecular and Cellular Biology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Interleukin-6-Specific Activation of the C/EBPδ Gene in Hepatocytes Is Mediated by Stat3 and Sp1
Carrie A. Cantwell, Esta Sterneck, Peter F. Johnson
Molecular and Cellular Biology Apr 1998, 18 (4) 2108-2117; DOI: 10.1128/MCB.18.4.2108
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • ADDENDUM IN PROOF
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acute-Phase Proteins
CCAAT-Enhancer-Binding Proteins
DNA-Binding Proteins
Gene Expression Regulation
Interleukin-6
liver
Nuclear Proteins
Sp1 Transcription Factor
Trans-Activators
transcription factors

Related Articles

Cited By...

About

  • About MCB
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #MCBJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0270-7306; Online ISSN: 1098-5549